Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Mark W Tenforde und 44 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Hospitalization, Emergency Service, Hospital. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, NIAID NIH HHS, CDC HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The 2023–2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses cocirculated. Seasonal influenza vaccine strains were well-matched to these viruses.
Methods
Using healthcare encounters data from health systems in 8 US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023 to April 2024. Using a test-negative design, we compared the odds of vaccination between patients with an acute respiratory illness who tested positive (cases) versus negative (controls) for influenza by molecular assay, adjusting for confounders. VE was stratified by age group, influenza type (overall, influenza A, influenza B), and care setting (hospitalization, emergency department or urgent care [ED/UC] encounter).
Results
Overall, 74 000 encounters in children and adolescents aged 6 months–17 years (3479 hospitalizations, 70 521 ED/UC encounters) and 267 606 in adults aged ≥18 years (66 828 hospitalizations, 200 778 ED/UC encounters) were included. Across care settings, among children and adolescents, 15% (2758/17 833) of cases versus 32% (18 240/56 167) of controls had received vaccination. Among adults, 25% (11 632/46 614) of cases versus 44% (97 811/220 992) of controls across care settings had received vaccination. VE was 58% (95% confidence interval [95% CI], 44–69) against hospitalization and 58% (95% CI, 56–60) against ED/UC encounters for children and adolescents, and 39% (95% CI, 35–43) against hospitalization and 47% (95% CI, 46–49) against ED/UC encounters for adults. Across age groups, VE was higher against influenza B than influenza A.
Conclusions
Influenza vaccines provided protection against influenza-associated illness across health care settings and age groups during the 2023–2024 influenza season.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Clinical Research Practice, Westat, Rockville, Maryland, USA.
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
- Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah, USA.
- Department of Research, HealthPartners Institute, Minneapolis, Minnesota, USA.
ORCID-Profile: Mark W Tenforde, Sara Y Tartof, Kristin Dascomb, Malini B DeSilva, Duck-Hye Yang, Shaun J Grannis, Stephanie A Irving, Toan C Ong, Ruth Link-Gelles, Lina S Sy, Bruno Lewin, Ousseny Zerbo, John Hansen, Daniel Bride, Inih J Essien, Brian E Dixon, Colin Rogerson, Allison L Naleway, Michelle A Barron, Suchitra Rao, Amanda B Payne, Caitlin Ray, Varsha Neelam, Katherine Adams, Jennifer DeCuir, Shikha Garg
Förderung
- Intramural CDC HHS
- NIAID NIH HHS
- CDC HHS
- Westat and contracts
- Kaiser Foundation Hospitals
- CDC
Zitieren
APA
Tenforde, M. W., Reeves, E. L., Weber, Z. A., Tartof, S. Y., Klein, N. P., Dascomb, K., DeSilva, M. B., Yang, D. H., Grannis, S. J., Irving, S. A., Ong, T. C., Link-Gelles, R., Salas, S. B., Sy, L. S., Lewin, B., Contreras, R., Zerbo, O., Fireman, B., Hansen, J., …, & Garg, S. (2025). Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae597
Vancouver
Tenforde MW, Reeves EL, Weber ZA, Tartof SY, Klein NP, Dascomb K, et al. Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae597
BibTeX
@article{Tenforde2025,
author = {Tenforde, Mark W and Reeves, Emily L and Weber, Zachary A and Tartof, Sara Y and Klein, Nicola P and Dascomb, Kristin and DeSilva, Malini B and Yang, Duck-Hye and Grannis, Shaun J and Irving, Stephanie A and Ong, Toan C and Link-Gelles, Ruth and Salas, S Bianca and Sy, Lina S and Lewin, Bruno and Contreras, Richard and Zerbo, Ousseny and Fireman, Bruce and Hansen, John and Timbol, Julius and Sheffield, Tamara and Bride, Daniel and Arndorfer, Julie and VanOtterloo, Josh and McEvoy, Charlene E and Akinsete, Omobosola O and Essien, Inih J and Dixon, Brian E and Rogerson, Colin and Fadel, William F and Duszynski, Thomas and Naleway, Allison L and Barron, Michelle A and Rao, Suchitra and Mayer, David and Chavez, Catia and Ball, Sarah W and Payne, Amanda B and Ray, Caitlin and Dickerson, Monica and Neelam, Varsha and Adams, Katherine and Flannery, Brendan and DeCuir, Jennifer and Garg, Shikha},
title = {Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae597}
}
EUVIMED